ProCE Banner Activity

Quick Guide to GLP-1 RA and GIP/GLP-1 Coagonists for T2D Care

PDF

Use this downloadable resource to guide treatment selection of GLP-1 RAs and GIP/GLP-1 coagonists in your clinical practice. This quick reference guide includes approved indications for use, dosing strategies, and key counseling points for your patients.

Released: September 27, 2024

Expiration: September 26, 2025

Share

Faculty

Richard E. Pratley

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Disclosure

Primary Author

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

Richard E. Pratley, MD: consultant/advisor/speaker: AbbVie, Altanine, AstraZeneca, Bayer AG, Bayer HealthCare, Boehringer Ingelheim, Corcept, Endogenex, Gasherbrum Bio, Genprex, Getz Pharma, Intas, Lilly, Lilly USA, Novo Nordisk, Pfizer, Rivus, Scholar Rock, Sun Pharmaceutical; researcher: Biomeda Fusion, Carmot Therapeutics, Dompe, Endogenex, Fractyl, Lilly, Novo Nordisk, Sanofi, Scholar Rock; individual publicly traded stocks/stock options: Altanine.